In this study we have found that in vivo PFC responses to Thy-1 are strongly modulated by H-2 gene products in at least 2 ways. First, a profound inhibition of primary PFC responses occurs when foreign H-2 antigens are expressed on Thy-1 incompatible donor cells. This interference effect does not reflect a requirement for H-2-restricted antigen presentation by donor cells, since it is also seen using semi-syngeneic antigenic cells that share a full H-2 haplotype with the recipient. Interference acts more profoundly on slower primary responses than on more rapid secondary responses and requires associative recognition of the H-2 and Thy-1 antigens. By contrast, strong augmentation of the anti-Thy-1 response was obtained when foreign H-2 antigens were expressed in the recipient, as shown by a poor response of an H-2k/k recipient to Thy-1.1 on AKR cells (H-2k) compared with high responses of H-2k/b recipients. A gene controlling this phenotype was mapped to the H-2IA or H-2K regions. However, subsequent experiments revealed that donor recognition of recipient H-2 antigens was required for these high responses; thus, an Ir-gene effect was excluded and an 'intimate form' of an allogeneic effect was postulated. Thus, the immune response to Thy-1 is regulated by at least 3 factors acting at the level of the donor cell, including non-H-2 helper alloantigens, H-2 interference, and H-2-associated allogeneic effects.

Download full-text PDF

Source

Publication Analysis

Top Keywords

h-2 antigens
12
h-2
8
pfc responses
8
foreign h-2
8
antigens expressed
8
donor cells
8
high responses
8
responses
7
donor
5
recipient
5

Similar Publications

In situ vaccine (ISV) can activate the anti-tumor immune system by inducing immunogenic cell death (ICD) at the tumor site. However, the development of tumor ISV still faces challenges due to insufficient tumor antigens released by tumor cells and the existence of tumor immunosuppressive microenvironment (TIME). Targeting the STING pathway has been reported to enhance the adjuvant effects of in situ tumor vaccines by initiating innate immunity.

View Article and Find Full Text PDF

Human recombination-activating gene (RAG) deficiency can manifest with distinct clinical and immunological phenotypes. By applying a multiomics approach to a large group of -mutated patients, we aimed at characterizing the immunopathology associated with each phenotype. Although defective T and B cell development is common to all phenotypes, patients with hypomorphic variants can generate T and B cells with signatures of immune dysregulation and produce autoantibodies to a broad range of self-antigens, including type I interferons.

View Article and Find Full Text PDF

Bimetallic nanoreactor mediates cascade amplification of oxidative stress for complementary chemodynamic-immunotherapy of tumor.

Biomaterials

December 2024

Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Department of Cardiology, Zhongnan Hospital, Wuhan University, Wuhan, 430072, PR China. Electronic address:

As a promising tumor treatment, chemodynamic therapy (CDT) can specifically catalyze HO into the cytotoxic hydroxyl radical (·OH) via Fenton/Fenton-like reaction. However, the limited HO and weakly acidic pH in tumor microenvironment (TME) would severely restrict the therapeutic efficiency of CDT. Here, a weakly acid activated, HO self-supplied, hyaluronic acid (HA)-functionalized Ce/Cu bimetallic nanoreactor (CBPNs@HA) is elaborately designed for complementary chemodynamic-immunotherapy.

View Article and Find Full Text PDF

Background: Peanut allergy (PA) is one of the most prevalent food allergies with a lack of favorable safety/efficacy treatment. A cucumber mosaic virus-like particle expressing peanut allergen component Ara h 2 (VLP Peanut) has been developed as a novel therapeutic approach for PA.

Objective: We assessed the tolerogenic properties and reactivity of VLP Peanut.

View Article and Find Full Text PDF

Dendritic cells (DCs) play a crucial role in initiating antitumor immune responses. However, in the tumor environment, dendritic cells often exhibit impaired antigen presentation and adopt an immunosuppressive phenotype, which hinders their function and reduces their ability to efficiently present antigens. Here, a dual catalytic oxide nanosponge (DON) doubling as a remotely boosted catalyst and an inducer of programming DCs to program immune therapy is reported.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!